As of 2025-11-13, the EV/EBITDA ratio of Creo Medical Group PLC (CREO.L) is -3.36. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CREO.L's latest enterprise value is 29.59 mil GBP. CREO.L's TTM EBITDA according to its financial statements is -8.80 mil GBP. Dividing these 2 quantities gives us the above CREO.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.9x - 14.0x | 10.2x |
| Forward P/E multiples | 9.5x - 12.8x | 10.6x |
| Fair Price | (16.23) - (23.31) | (18.29) |
| Upside | -245.9% - -309.6% | -264.4% |
| Date | EV/EBITDA |
| 2025-11-12 | -3.38 |
| 2025-11-11 | -3.44 |
| 2025-11-10 | -3.45 |
| 2025-11-07 | -3.46 |
| 2025-11-06 | -3.37 |
| 2025-11-05 | -3.20 |
| 2025-11-04 | -3.44 |
| 2025-11-03 | -3.45 |
| 2025-10-31 | -3.46 |
| 2025-10-30 | -3.43 |
| 2025-10-29 | -3.44 |
| 2025-10-28 | -3.44 |
| 2025-10-27 | -3.39 |
| 2025-10-24 | -3.34 |
| 2025-10-23 | -3.31 |
| 2025-10-22 | -3.32 |
| 2025-10-21 | -3.21 |
| 2025-10-20 | -3.19 |
| 2025-10-17 | -3.46 |
| 2025-10-16 | -3.43 |
| 2025-10-15 | -3.38 |
| 2025-10-14 | -3.38 |
| 2025-10-13 | -3.39 |
| 2025-10-10 | -3.46 |
| 2025-10-09 | -3.43 |
| 2025-10-08 | -3.49 |
| 2025-10-07 | -3.68 |
| 2025-10-06 | -3.68 |
| 2025-10-03 | -3.69 |
| 2025-10-02 | -3.61 |
| 2025-10-01 | -3.73 |
| 2025-09-30 | -3.73 |
| 2025-09-29 | -3.91 |
| 2025-09-26 | -3.87 |
| 2025-09-25 | -3.78 |
| 2025-09-24 | -3.91 |
| 2025-09-23 | -3.79 |
| 2025-09-22 | -3.73 |
| 2025-09-19 | -3.87 |
| 2025-09-18 | -3.84 |
| 2025-09-17 | -3.85 |
| 2025-09-16 | -3.85 |
| 2025-09-15 | -3.91 |
| 2025-09-12 | -3.81 |
| 2025-09-11 | -4.02 |
| 2025-09-10 | -4.08 |
| 2025-09-09 | -4.09 |
| 2025-09-08 | -4.22 |
| 2025-09-05 | -4.28 |
| 2025-09-04 | -4.25 |